Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – Time to Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) shares saw an uptick in trading volume on Tuesday . 2,633,329 shares changed hands during mid-day trading, an increase of 53% from the previous session’s volume of 1,716,444 shares.The stock last traded at $27.3840 and had previously closed at $27.91.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GMAB. Guggenheim reduced their target price on Genmab A/S from $45.00 to $40.00 and set a “buy” rating for the company in a report on Monday, February 23rd. Truist Financial upgraded Genmab A/S to a “strong-buy” rating in a report on Wednesday, March 25th. HC Wainwright boosted their target price on Genmab A/S from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. Jefferies Financial Group began coverage on Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price for the company. Finally, Morgan Stanley began coverage on Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.36.

Genmab A/S Trading Down 2.6%

The company has a market capitalization of $17.47 billion, a price-to-earnings ratio of 17.54, a price-to-earnings-growth ratio of 1.29 and a beta of 0.97. The business has a fifty day moving average price of $27.90 and a 200 day moving average price of $30.36. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.41). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. On average, equities analysts expect that Genmab A/S Sponsored ADR will post 1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Founders Capital Management lifted its holdings in shares of Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock worth $43,000 after buying an additional 400 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Genmab A/S by 11.3% during the third quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock valued at $127,000 after purchasing an additional 419 shares during the period. CWM LLC increased its position in shares of Genmab A/S by 18.8% during the fourth quarter. CWM LLC now owns 2,739 shares of the company’s stock valued at $84,000 after purchasing an additional 433 shares during the period. Jones Financial Companies Lllp increased its position in shares of Genmab A/S by 29.1% during the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after purchasing an additional 440 shares during the period. Finally, Osaic Holdings Inc. increased its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.